本文字数：2121，阅读时长大约4分钟 2026.02. 03 作者 | 第一财经 秦新安 这是本月国家医保局曝光的第四起典型回扣案。在此之前，国家医保局已先后曝光黑龙江省双丰林业局职工医院内科医生党某海犯非国家工作人员受贿 罪案、重庆康荣医疗设备有限公司实际控制人王某向重庆某医院院长孙某行贿案，以及山东某医用高分子制品公司业务员慈某龙向普洱市人民医院工作 人员行贿案。几起案件暴露了医药商业贿赂的猖獗，也展示了医保部门打击医药商业贿赂、维护医保基金安全的决心。 国家医保局指出，医药商业贿赂本质上是通过给予不正当利益影响处方权，干扰正常诊疗行为，妨碍公平竞争，加重医药负担，使得医药产品销售从实 际临床价值和产品竞争力的竞争，转为以高返点和高回扣驱动的不当竞争。陕西李某受贿案就呈现医药商业贿赂的典型特征。一方面，受贿方利用科室 主任对科室使用耗材的决策权，在众多可选产品中优先选用给予高额回扣的贴牌耗材；另一方面，行贿方将事先约定回扣计入供货成本，最终通过医保 基金与患者自付"埋单"。 医药商业贿赂屡禁不止，背后是复杂的利益链条与制度漏洞。长期以来，在部分医疗领域，特别是高值耗材与药品销售中，"带金销售"成为一些企 ...

Group 1 - The core viewpoint of the article highlights the transformation of traditional manufacturing through digitalization and automation, exemplified by the advancements in the shoe manufacturing and electrical industries in Weihai [1][5]. - Jinmon Group's digital intelligent shoe factory has successfully completed trial production, utilizing advanced robotic systems to enhance efficiency and reduce labor costs by over 30% while increasing production efficiency by 30% [1][4]. - The integration of intelligent robots with the MES system addresses long-standing issues in order scheduling, task tracking, and data aggregation, leading to a fully traceable production process and quality assurance [4]. Group 2 - Weihai High-tech Zone is accelerating the resolution of traditional manufacturing bottlenecks through intelligent transformation, with several companies recognized for their advanced manufacturing capabilities [5]. - The region has created a supportive environment for smart manufacturing, establishing four provincial-level excellent intelligent manufacturing scenarios and eight digital workshops [5]. - Policies such as technical transformation subsidies and demonstration rewards are encouraging companies to invest in intelligent upgrades, fostering a comprehensive ecosystem for smart transformation [5].

Core Viewpoint - The company plans to issue shares to acquire 100% equity of Shandong Weigao Puri Pharmaceutical Packaging Co., Ltd. from related parties, which constitutes a significant asset restructuring under regulatory guidelines [1] Group 1: Transaction Details - The transaction involves the acquisition of equity from Shandong Weigao Group Medical Polymer Co., Ltd., Weihe Shengxi Enterprise Management Consulting Center (Limited Partnership), and Weihe Ruiming Enterprise Management Consulting Partnership (Limited Partnership) [1] - This transaction is classified as a related party transaction and is subject to various approvals, including the board of directors, shareholders' meeting, Shanghai Stock Exchange, and China Securities Regulatory Commission [1] Group 2: Financial Status - As of the date of the announcement, the audit and evaluation of the target assets have not been completed, and the relevant financial data and transaction price are yet to be determined [1]

Group 1 - The stock price of Zhonghong Medical is reported at 15.95 yuan, down 0.01 yuan from the previous trading day, with a decline of 0.06% [1] - The opening price for the day was 16.10 yuan, reaching a high of 16.15 yuan and a low of 15.75 yuan, with a trading volume of 98,899 hands and a transaction amount of 1.57 billion yuan [1] - Zhonghong Medical operates in the medical device sector, focusing on the research, production, and sales of medical polymer products, including disposable sterile syringes and infusion devices [1] Group 2 - The subsidiary Shenzhen Maide Ruina recently obtained a medical device registration certificate for infusion pumps from the Guangdong Provincial Drug Administration [1] - The infusion pump is designed to be used with infusion lines for intravenous medication delivery, excluding analgesics, chemotherapy drugs, and insulin, and can also be used with enteral nutrition infusion lines for adjustable nutrient delivery [1] Group 3 - On August 22, the net outflow of main funds was 23.52 million yuan, accounting for 0.38% of the circulating market value [1] - Over the past five days, the cumulative net outflow of main funds reached 59.99 million yuan, representing 0.96% of the circulating market value [1]